MedTrace Logo

The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects

NCT05786066 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-05-06

No results posted yet for this study

Summary

The purpose of this study is to test the hypothesis that the anti-depressant and anti-suicidal effects of the N-methyl-D-aspartate receptor (NMDAR) antagonist Ketamine is critically dependent on stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4-Isoxazole Propionic Acid receptors (AMPAR).

Conditions

Interventions

DRUG

Perampanel 6 MG

Perampanel will be administered 2.5 hours before Ketamine infusion

DRUG

Ketamine

Ketamine infusion (0.5 mg/kg infusion over 40 minutes) will be administered 2.5 hours post perampanel or placebo administration.

DRUG

Placebo

Placebo will be administered 2.5 hours before Ketamine infusion

Sponsors & Collaborators

  • American Foundation for Suicide Prevention

    collaborator OTHER

  • National Center for PTSD

    collaborator FED

  • VA Connecticut Healthcare System

    collaborator FED

  • Yale University

    lead OTHER

Principal Investigators

  • Naomi Driesen, PhD · Yale University / VACHS West Haven

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-03
Primary Completion
2033-03-31
Completion
2033-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05786066 on ClinicalTrials.gov